GLP-1 has become one of the best-known terms in medicine.
But for someone who doesn’t follow pharmaceutical research closely, the terminology can get confusing quickly.
GIP agonist.
Dual agonist.
Triple agonist.
And lately, a compound called retatrutide is sometimes being described online as “GLP-3.”
So what does all of this actually mean?
The easiest way to understand the field is to start with receptors.
Hormones Send Messages
Your body is constantly sending chemical messages.
Some messages tell cells that nutrients have arrived.
Others help regulate blood glucose, digestion, appetite, growth, stress, sleep, and many other processes.
Many of these signals are hormones.
Some hormones are peptides.
A peptide hormone travels through the body and interacts with a specific molecular target called a receptor.
You can think of the hormone as a message and the receptor as the system designed to receive it.
Once the receptor is activated, the cell responds.
GLP-1 Is One of Those Signals
GLP-1 stands for glucagon-like peptide-1.
It is a naturally occurring peptide hormone.
GLP-1 receptor signaling has several roles in metabolism, including effects on glucose-dependent insulin secretion, glucagon regulation, appetite, and gastrointestinal function.
Scientists learned that they could create molecules that activate the same GLP-1 receptor but last much longer than natural GLP-1.
These are called GLP-1 receptor agonists.
Semaglutide is one well-known example.
What Does “Agonist” Mean?
An agonist is simply a molecule that activates a receptor.
It doesn’t have to be identical to the natural hormone.
Scientists can design a synthetic molecule that binds to a receptor and produces a similar or modified biological signal.
That gives researchers room to change properties such as:
- how long the molecule lasts
- how strongly it activates the receptor
- how it is distributed
- how resistant it is to enzymatic breakdown.
This is one of the basic ideas behind modern peptide drug research.
Then Researchers Began Targeting Two Receptors
The next important step was dual agonism.
Tirzepatide is a prominent example.
Instead of targeting only GLP-1R, tirzepatide activates:
GLP-1R + GIPR
GIP stands for glucose-dependent insulinotropic polypeptide.
Like GLP-1, it is an incretin hormone associated with nutrient-dependent metabolic signaling.
So tirzepatide combines two receptor pathways in one molecule.
Research into dual and triple incretin-based agonists has expanded rapidly, with clinical trials showing that multi-receptor approaches can produce substantial metabolic effects.
What Comes After a Dual Agonist?
This is where retatrutide comes in.
Retatrutide is designed to activate three receptors:
GIPR + GLP-1R + GCGR
GCGR is the glucagon receptor.
That makes retatrutide a triple hormone receptor agonist.
It is also why the popular nickname “GLP-3” is misleading.
There isn’t a new GLP-3 receptor involved.
Lilly explicitly describes “GLP-3” as an informal and scientifically inaccurate term. Retatrutide instead combines signaling at the GIP, GLP-1, and glucagon receptors.
Why Would Scientists Add the Glucagon Receptor?
This is probably the least intuitive part.
Many people have heard that glucagon can increase blood glucose.
That’s true.
So why would researchers deliberately add glucagon receptor activity to a molecule being studied in metabolic disease?
Because glucagon has other effects too.
Glucagon signaling is involved in:
- liver metabolism
- fat metabolism
- amino-acid metabolism
- energy expenditure.
The research idea is that GIP and GLP-1 signaling can provide one set of metabolic effects while glucagon receptor activation may add additional effects on energy use and nutrient metabolism.
The actual human biology is more complicated than that simple explanation, but it captures the reason triple agonism became interesting.
One Molecule Can Carry Several Signals
This is perhaps the most fascinating part for someone new to peptides.
Retatrutide isn’t three separate medications combined in one container.
It is a single engineered peptide molecule.
Scientists altered the molecular structure so that the same peptide can interact with all three target receptors.
Lilly currently describes LY3437943, or retatrutide, as a biologic entity acting as a triagonist at GIPR, GLP-1R, and GCGR.
This kind of design is sometimes called unimolecular polyagonism.
That’s a complicated phrase for a fairly simple concept:
one molecule, multiple receptor targets.
Does Triple Mean Three Times Stronger?
No.
This is one of the easiest misconceptions to make.
A triple agonist is not automatically three times stronger than a single agonist.
The receptors do different things.
And retatrutide does not even activate all three receptors with identical potency.
The overall effect depends on a combination of:
- receptor potency
- receptor expression
- drug concentration
- tissue exposure
- pharmacokinetics
- interactions among biological pathways.
Adding a receptor can improve an experimental result, do nothing useful, or introduce undesirable effects.
The challenge is finding the right balance.
Why Are Researchers So Interested in Retatrutide?
The simple answer is that its clinical results have been large enough to attract attention.
In Lilly’s Phase 3 TRIUMPH-1 obesity trial, participants assigned to the 12 mg group had an average body-weight reduction of 28.3% at 80 weeks under the study’s efficacy estimand.
Additional Phase 3 studies have reported results in people with type 2 diabetes and in those with severe obesity and established cardiovascular disease. Retatrutide is also being studied in areas such as obstructive sleep apnea, knee osteoarthritis, kidney and cardiovascular outcomes, chronic low back pain, and liver disease.
But this is an important point:
Retatrutide is still investigational.
It is not an FDA-approved medication as of September 2026.
Clinical Research and Laboratory Research Aren’t the Same Thing
Someone reading about peptides online will often encounter both clinical trials and commercial research reagents.
These should not be confused.
A pharmaceutical company’s clinical-trial material is produced for use under a controlled research protocol.
A laboratory research product is a chemical reagent intended for experimental work.
For example, a retatrutide research peptide can be supplied for analytical and laboratory research, but that does not make the material equivalent to Lilly’s investigational clinical formulation.
Differences may include:
- manufacturing controls
- formulation
- excipients
- sterility requirements
- quality specifications.
That boundary is important when reading about experimental peptides.
How Do Researchers Verify a Peptide?
Knowing the molecule’s name isn’t enough.
Scientists also need to know whether the physical material they’re studying is what it claims to be.
Two common analytical tools are HPLC and mass spectrometry.
HPLC
HPLC stands for high-performance liquid chromatography.
It separates different components in a sample.
Researchers can use the resulting chromatogram to estimate the relative amount of the main peptide peak compared with other detected peaks.
This is one common source of statements such as:
99% purity by HPLC.
Mass Spectrometry
Mass spectrometry gives researchers information about molecular mass.
They can compare the experimentally observed molecular mass with what is expected from the peptide’s chemical structure.
That provides another piece of evidence supporting identity.
Neither method answers every quality question by itself.
Why Does the Lot Number Matter?
Imagine a supplier manufactures a peptide in January and again in July.
They’re the same named compound, but they’re not the same batch.
A test performed on the January material doesn’t automatically prove the analytical characteristics of the July material.
That’s why research products are often assigned lot numbers.
The useful chain is:
Product → Lot Number → Test Report
That makes it possible to connect a physical sample with its analytical documentation.
Why Are Some Peptides Sold as Dry Powder?
Many research peptides are supplied in a dry, lyophilized form.
Lyophilization means freeze-drying.
Removing water can improve stability for some materials because many degradation processes are easier when water is present.
But “freeze-dried” doesn’t mean indestructible.
Peptides can still be affected by:
- heat
- moisture
- oxygen
- light
- time.
And different peptide sequences can have very different stability profiles.
This is one reason scientific storage recommendations need to be compound-specific.
Are Peptides Proteins?
They’re closely related.
Both peptides and proteins are made from amino acids connected by peptide bonds.
Proteins are generally larger and often fold into more elaborate three-dimensional structures.
There is no single universally useful line where every scientist agrees that a chain stops being a peptide and becomes a protein. The National Library of Medicine describes peptides and proteins as part of the same broader family of amino-acid chains, with proteins generally representing larger, more structurally complex molecules.
So peptides can be thought of as smaller relatives within the same broad biochemical world.
Why Not Just Use Natural Peptides?
Sometimes scientists do.
But natural peptides often have properties that make them challenging as long-lasting research or pharmaceutical compounds.
They may:
- break down rapidly
- disappear from circulation quickly
- have poor membrane penetration
- have limited stability.
Researchers can modify peptides to change those characteristics.
A synthetic peptide might use altered amino acids, lipid groups, or other modifications to extend its biological lifetime or change receptor interactions.
Modern reviews identify enzymatic degradation and delivery as major challenges in peptide development and describe extensive research aimed at overcoming them.
Does More Receptors Mean the Future Will Be Quadruple or Quintuple Agonists?
Possibly, but there is no rule saying that more is automatically better.
Researchers are already exploring increasingly complex multi-receptor molecules.
But every added target makes the pharmacology more difficult to balance.
A successful molecule must have the right:
- receptor activity
- stability
- duration
- tissue exposure
- safety profile.
You could design a peptide that activates five receptors and still have a less useful molecule than one targeting a single receptor extremely well.
The number of receptors is only one design choice.
What Retatrutide Really Represents
For someone interested in peptides, the most interesting part of retatrutide may not ultimately be one clinical endpoint.
It is what the molecule represents scientifically.
A few decades ago, much peptide research focused on identifying and understanding natural peptide hormones.
Researchers can now increasingly take that knowledge and build new signaling molecules.
They can alter sequences.
They can extend half-life.
They can change receptor potency.
And they can combine biological activities that normally belong to different hormones.
Retatrutide is a current example of that shift.
Conclusion
The evolution from GLP-1 agonists to dual and triple agonists is really a story about increasingly sophisticated peptide engineering.
A GLP-1 receptor agonist focuses mainly on one signaling pathway.
A dual agonist such as tirzepatide combines GIP and GLP-1 receptor signaling.
Retatrutide adds glucagon receptor activity, creating one engineered molecule that can activate three related metabolic receptors.
That does not make a triple agonist automatically superior.
It does make the science more interesting.
Researchers are effectively asking whether carefully balancing several biological signals within one peptide can create useful effects that would be difficult to produce by targeting just one pathway.
Retatrutide remains investigational, so that scientific story is still being written.
But it already shows why peptides have become such an active area of modern biological and pharmaceutical research.
References
Eli Lilly and Company. What to Know About Retatrutide.
Eli Lilly and Company. Retatrutide Clinical Development Pipeline.
Eli Lilly and Company. TRIUMPH-1 Phase 3 Results.
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Evolution of Incretin-Based Therapies: From GLP-1 Monotherapy to Dual and Triple Agonists.
